Principia Biopharma Inc. (PRNB) News

Principia Biopharma Inc. (PRNB): $100.05

0.10 (+0.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter PRNB News Items

PRNB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PRNB News From Around the Web

Below are the latest news stories about Principia Biopharma Inc that investors may wish to consider to help them evaluate PRNB as an investment opportunity.

dosing underway for Principia's rilzabrutinib mid-stage study in IgG4-related disease

Principia Biopharma (PRNB) has dosed the first patient in an open label two-arm Phase 2A trial, evaluating rilzabrutinib in IgG4-related disease ((RD)), an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs.The 25-subject trial has a primary endpoint of the proportion of patients who achieve complete remission at week 12 with...

Seeking Alpha | September 17, 2020

A biopharma with 54% upside, with or without M&A - Evercore

Chatter about a potential buyout has lifted the stock of immune-disorder therapy developer Principia Biopharma (PRNB) - shares are up 13.6% since Sanofi (SNY) was linked to interest, and they're up 49% over the past three weeks - but a takeover isn't even part of the thesis in a bullish...

Seeking Alpha | July 29, 2020

Why Principia Could Be the Next Target of Sanofi's Makeover

Buyout rumors have spurred a sharp increase in the small biotech’s shares Continue reading...

Yahoo | July 19, 2020

Principia Biopharma Soars as Sanofi Is Said to Seek Deals

Sanofi is reportedly looking at potential acquisitions of U.S. biotechs. Principia Biopharma shares jumped on the report.

Yahoo | July 16, 2020

Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%

Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Yahoo | July 16, 2020

Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis

Upon dosing, Principia will be entitled to a $50 million milestone payment. SAR442168, discovered by Principia and formerly known as PRN2246, is a Bruton’s tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the central nervous system (CNS), which shows promise for the potential treatment of CNS diseases.

Yahoo | June 23, 2020

Hedge Funds Have Never Been This Bullish On Principia Biopharma Inc. (PRNB)

In this article you are going to find out whether hedge funds think Principia Biopharma Inc. (NASDAQ:PRNB) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | June 18, 2020

Principia's rilzabrutinib shows positive response in immune thrombocytopenia

Principia Biopharma ([[PRNB]] +2.9%) announces positive data on durability of response from an ongoing Phase 1/2 trial of its investigational treatment, rilzabrutinib at the European Hematology Association.A total of 47 heavily pre-treated patients with immune thrombocytopenia ((ITP)) have been enrolled with a median follow-up of 18 weeks. The primary endpoint was...

Seeking Alpha | June 12, 2020

Principia's rilzabrutinib shows positive effect in rare skin-blistering disorder

Principia Biopharma (PRNB) announces positive results from Part B of a Phase 2 clinical trial, BELIEVE-PV, evaluating oral BTK inhibitor rilzabrutinib in patients with pemphigus, a group of rare autoimmune disorders characterized by blisters or sores on the skin. The data were virtually presented at the American Academy of Dermatology...

Seeking Alpha | June 12, 2020

The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.Negative clinical readouts led to some strong selling in stocks such as Iterum Therapeutics PLC (NASDAQ: ITRM) and Novus Therapeutics Inc (NASDAQ: NVUS). On a positive note, Merck & Co., Inc. (NYSE: MRK) snagged another approval for its triple combo antibiotic.Here are are the key catalysts for the unfolding week.Conferences * Bio Digital: June 8-12 * 41st Annual Goldman Sachs Global Healthcare Conference, held as a virtual event: June 9-11 * The Endocrine Society's ENDO Online 2020: June 8-22 * 25th Edition of the European Hematology Association, or EHA, Annual Congress held in virtual format: June 11-21 * American Academy of Dermatology, or AAD, Virtual Mee...

Yahoo | June 7, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6771 seconds.